EPZ-6438, another EZH2 inhibitor also known as Tazemetostat, selectively kills NHL cells bearing mutations within EZH2, and it has minimal effects on the proliferation of EZH2 wild-type NHL cells. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.